

Therapeutic Goods (Biologicals—Authorised Supply) Rules 2022

I, Nicholas Henderson, as delegate of the Minister for Health and Aged Care, make the following rules.

Dated 15 December 2022

Nicholas Henderson

Acting First Assistant Secretary

Medicines Regulation Division

Health Products Regulation Group

Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Definitions 1

5 Authorisation 2

Schedule 1—Biologicals authorised for supply 4

Schedule 2—Repeals 6

Therapeutic Goods (Biologicals—Authorised Supply) Rules 2020 6

1 Name

 This instrument is the *Therapeutic Goods (Biologicals—Authorised Supply) Rules 2022.*

2 Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument. | The day after this instrument is registered. |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 32CM(7A) of the *Therapeutic Goods Act 1989*.

4 Definitions

Note: A number of expressions used in this instrument are defined in subsection 3(1) of the Act, including the following:

(a) biological;

(b) health practitioner;

(c) included in the Register;

(d) Register;

(e) sponsor;

(f) supply.

 In this instrument:

***Act*** means the *Therapeutic Goods Act 1989*.

***SAS Guidance*** means the document titled *Special Access Scheme Guidance for health practitioners and sponsors* (Version 1.1, September 2017) published by the Therapeutic Goods Administration, as in force or existing at the commencement of this instrument.

Note: The SAS Guidance is published at www.tga.gov.au.

***Therapeutic Goods Administration*** has the same meaning as in the *Therapeutic Goods Regulations 1990*.

5 Authorisation

Supply by a specified health practitioner

 (1) A health practitioner specified in column 5 of an item in the table in Schedule 1 is authorised to supply a biological to a patient of that practitioner where:

 (a) the biological is specified in column 2 of that item; and

 (b) the biological is to be administered by the route specified in column 3 of that item; and

 (c) the supply is for the indication specified in column 4 of that item; and

 (d) the conditions specified in subsection (2) are satisfied.

 (2) The health practitioner must:

 (a) inform the patient, or a parent or guardian of the patient, that the biological is not included in the Register; and

 (b) obtain informed consent from the patient, or a parent or guardian of the patient, in relation to, and before, the supply of the biological; and

 (c) supply the biological in accordance with good medical practice or the relevant code of conduct for the health practitioner; and

 (d) if the health practitioner becomes aware that the patient has suffered an adverse event in relation to the biological—notify the Therapeutic Goods Administration and the sponsor of the biological about the adverse event in accordance with the reporting guidelines set out in the SAS Guidance; and

 (e) if the health practitioner becomes aware of a defect in the biological—notify the Therapeutic Goods Administration and the sponsor of the biological in accordance with the reporting guidelines set out in the SAS Guidance.

Supply to a patient of a specified health practitioner

 (3) A health practitioner is authorised to supply a biological to a patient of a health practitioner specified in column 5 of an item in the table in Schedule 1 (the ***treating practitioner***) where:

 (a) the biological is specified in column 2 of that item; and

 (b) the supply is requested by the treating practitioner; and

 (c) the biological is to be administered by the route specified in column 3 of that item; and

 (d) the supply is for the indication specified in column 4 of that item; and

 (e) the conditions specified in subsection (4) are satisfied.

 (4) The health practitioner supplying the biological must:

 (a) if the health practitioner becomes aware that the patient has suffered an adverse event in relation to the biological—notify the Therapeutic Goods Administration and the sponsor of the biological about the adverse event in accordance with the reporting guidelines set out in the SAS Guidance; and

 (b) if the health practitioner becomes aware of a defect in the biological—notify the Therapeutic Goods Administration and the sponsor of the biological in accordance with the reporting guidelines set out in the SAS Guidance.

**6 Repeals**

 Each instrument that is specified in Schedule 2 is repealed as set out in the applicable items in that Schedule.

Schedule 1—Biologicals authorised for supply

Note: See section 5.

| Specified therapeutic goods |
| --- |
| Column 1 | Column 2 | Column 3 | Column 4 | Column 5 |
| Item | Biological | Route of administration | Indication | Health practitioner  |
| 1 | AlloDerm GBR RTM (human skin tissue matrix) | intra-oral graft | graft protection and containment,flap extender to achieve primary closure, or gingival augmentation | dental practitioner |
| 2 | AlloDerm RTM (human skin tissue matrix) | intra-oral graft | root coverage, gingival augmentationsoft tissue ridge augmentation, orsoft tissue augmentation around implants | dental practitioner |
| 3 | Amniotic Membrane | ophthalmic | ocular conditions  | medical practitioner |
| 4 | Grafton DBM Matrix (demineralised human bone tissue) | intra-oral graft | extraction socket grafting, ridge and sinus augmentation, bone augmentation around implants, bony defects, composite grafting, or filling of periodontal defects | dental practitioner |
| 5 | MinerOss Cancellous (human bone allograft) | intra-oral graft | ridge and sinus augmentation, extraction socket grafting, or bony defects | dental practitioner |
| 6 | MinerOss cortical and cancellous (human bone allograft) | intra-oral graft | ridge and sinus augmentation, extraction socket grafting, or bony defects | dental practitioner |
| 7 | MinerOss Cortical (human bone allograft) | intra-oral graft | ridge and sinus augmentation, extraction socket grafting, or bony defects | dental practitioner |
| 8 | Ortho-ATI (tenocytes) cell suspension | intratendinous injection | treatment of chronic lateral epicondylitis or gluteal tendinopathy (> 6 months) with or without partial tendon tear, that is not responsive to conservative treatment | orthopaedic surgeon |
| 9 | Puros Cancellous Particulate Allograft (human bone tissue) | intra-oral graft | ridge and sinus augmentation, extraction socket grafting, or bony defects | dental practitioner |
| 10 | Puros Cortical Particulate Allograft (human bone tissue) | intra-oral graft | ridge and sinus augmentation, extraction socket grafting, or bony defects | dental practitioner |
| 11 | Tutoplast Pericardium (sterilised human tissue allograft)  | topical | soft tissue graft | medical practitioner  |

Schedule 2—Repeals

Note: See section 6.

Therapeutic Goods (Biologicals—Authorised Supply) Rules 2020

1 The whole of the instrument

Repeal the instrument